Minocycline in phenotypic models of Huntington's disease
- 2 December 2004
- journal article
- Published by Elsevier in Neurobiology of Disease
- Vol. 18 (1) , 206-217
- https://doi.org/10.1016/j.nbd.2004.09.017
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal DegenerationPublished by Elsevier ,2003
- Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration InducedIn Vivoby 3-Nitropropionate: Implications for Huntington's DiseaseJournal of Neuroscience, 2003
- The Adenosine A1Receptor Agonist Adenosine Amine Congener Exerts a Neuroprotective Effect against the Development of Striatal Lesions and Motor Impairments in the 3-Nitropropionic Acid Model of NeurotoxicityJournal of Neuroscience, 2002
- Striatal and Cortical Neurochemical Changes Induced by Chronic Metabolic Compromise in the 3-Nitropropionic Model of Huntington's DiseaseNeurobiology of Disease, 2002
- Neuroprotective effect of interleukin‐6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndromeEuropean Journal of Neuroscience, 2001
- Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis ratNeuroReport, 2001
- Energetics in the pathogenesis of neurodegenerative diseasesPublished by Elsevier ,2000
- A novel mechanism of action of tetracyclines: Effects on nitric oxide synthasesProceedings of the National Academy of Sciences, 1996
- Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acidJournal of Neuroscience, 1993
- Replication of the neurochemical characteristics of Huntington's disease by quinolinic acidNature, 1986